Trevi Therapeutics

Trevi Therapeutics to Present at Stifel Healthcare Conference

November 14, 2019

NEW HAVEN, Conn., Nov. 13, 2019 (GLOBE NEWSWIRE) — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on […]

September 7, 2019

Advancement of Nalbuphine ER Through Clinical Development in Multiple Indications New Haven, CT, August 12, 2019– Trevi Therapeutics, Inc. (Nasdaq:

September 5, 2019

NEW HAVEN, Conn., Sept. 05, 2019 (GLOBE NEWSWIRE) — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on

September 27, 2018

Pruritus Relief thru Itch-Scratch Modulation (“PRISM”) Trial to enroll 240 patients and evaluate efficacy of Nalbuphine ER at 14 weeks

March 21, 2018

New Haven, CT, March 21, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage clinical development company focused on developing Nalbuphine®

October 12, 2017

Highly experienced clinical drug developer to oversee R&D functions and Company’s Phase 3 development program New Haven, CT, October 12,